Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial

R Eccles, B Winther, S L Johnston, P Robinson, M Trampisch, S Koelsch, R Eccles, B Winther, S L Johnston, P Robinson, M Trampisch, S Koelsch

Abstract

Iota-carrageenan (I-C) is active against respiratory viruses in vitro and was effective as nasal spray in three previous clinical trials. The current trial served to further investigate I-C in patients with early common cold symptoms.

Methods: This randomized, placebo-controlled, double-blind phase IV trial was conducted in 200 adult patients with self-diagnosed colds of <48 h' duration that were confirmed by baseline cold symptom scores. Patients were to self-administer 0.12 % I-C or placebo spray (NaCl 0.5 %) four times daily for four to ten days and record symptom information for ten days. Common respiratory viruses were quantified by RT-PCR during pretreatment and on Day 3 or 4. The primary endpoint was the mean total symptom score (TSS) of eight cold symptoms on Days 2-4 (TSS2-4).

Results: Patients in both treatment groups had similar baseline TSSs (mean TSS: 6.75 for I-C and 6.79 for placebo). Viruses were detected in baseline samples from 53 of 98 I-C patients (54.1 %) and 54 of 97 placebo patients (55.7 %). Mean ± SE for TSS2-4 was 5.78 ± 0.25 for I-C patients and 6.39 ± 0.25 for placebo (p = 0.0895). Exploratory analyses after unblinding (TSS2-4 excluding a patient with aberrantly high symptom scores [TSS2-4, ex 1pt]; mean of TSS over Days 1-4 [TSS1-4]; change in TSS1-4 relative to baseline [TSS1-4, rel]) demonstrated treatment differences in favor of I-C (p = 0.0364, p = 0.0495 and p = 0.0421, respectively). For patients with quantifiable rhinovirus/enterovirus at baseline, there was a trend towards greater reduction of virus load at Day 3 or 4 (p = 0.0958; I-C: 90.2 % reduction in viral load; placebo: 72.0 %). Treatments were well tolerated with no differences in adverse event rates.

Conclusions: The primary endpoint did not demonstrate a statistically significant difference between I-C and placebo but showed a trend towards I-C benefit. Exploratory analyses indicated significant reduction of cold symptoms in the I-C group relative to placebo during the first four days when symptoms were most severe, and also substantiated I-C's activity against rhinovirus/enterovirus.

Trial registration: NCT01944631 (clinicaltrials.gov).

Figures

Fig. 1
Fig. 1
Disposition of trial patients. 1Placebo (PBO), 2Full analysis set, 3One patient with extreme outlier TSS baseline scores was excluded from some exploratory analyses, 4Virus positive patients were those with a positive qualitative test at baseline and/or a detectable quantitative (quantifiable or non-quantifiable) result on a quantitative test at baseline, 5Defined as a detectable quantitative (quantifiable or non-quantifiable) result on panentorhino/Ge/08 assay, 6Quantifiable result on panenterhino/Ge/08 assay
Fig. 2
Fig. 2
Adjusted mean TSS values with standard error for each day of the trial (data at baseline are displayed as unadjusted mean values)

References

    1. Mäkelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998;36:539–542.
    1. Fendrick MA, Monto AS, Nightengale B, Sarnes M. The Economic Burden of Non–Influenza-Related Viral Respiratory Tract Infection in the United States. Arch Intern Med. 2003;163:487–94. .
    1. Leibbrandt A, König-Schuster M, Weinmüllner R, Kalthoff D, Pflugfelder B, Graf P, et al. Iota-Carrageenan is a potent inhibitor of influenza A virus infection. PLoS One. 2010;5:e14320. .
    1. Grassauer A, Weinmuellner R, Meier C, Pretsch A, Prieschl-Grassauer E, Unger H. Iota-carrageenan is a potent inhibitor of rhinovirus infection. Virol J. 2008;5:107. .
    1. Eccles R, Meier C, Jawad M, Weinmueller R, Grassauer A, Prieschl-Grassauer E. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir Res (Lond). 2010;11:108.
    1. Fazekas T, Eickhoff P, Pruckner N, Vollnhofer G, Fischmeister G, Diakos C, et al. Lessons learned from a double-blind randomised placebo-controlled study with an iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold. BMC Complement Altern Med. 2012;12:147. .
    1. Ludwig M, Enzenhofer E, Schneider S, Rauch M, Bodenteich A, Neumann K, et al. Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial. Respir Res (Lond). 2013;14:124. .
    1. Jackson GG, Dowling HF, Spiesman IG, Boand AV. Transmission of the common cold to volunteers under controlled conditions. Intern Med. 1958;101:267–278.
    1. Allen EK, Pitkaranta A, Maki M, Hendley JO, Laakso S, Sale MM, Winther B. Bacteria in the nose of young adults during wellness and rhinovirus colds- detection by cultures and microarray methods in 100 nasal lavage specimens. Int Forum Allergy Rhinol. 2013;9:731–39.
    1. Tapparel C, Cordey S, Van Belle S, Turin L, Lee WM, Regamey N, et al. New Molecular Detection Tools Adapted to Emerging Rhinoviruses and Enteroviruses. J Clin Microbiol. 2009;47:1742. .
    1. Schibler M, Yerly S, Vieille G, Docquier M, Turin L, Kaiser L, Tapparel C. Critical Analysis of Rhinovirus RNA Load Quantification by Real-Time Reverse Transcription-PCR. J Clin Microbiol. 2012;50:2868. .
    1. Garbino J, Crespo S, Aubert JD, Rochat T, Ninet B, Deffernez C, et al. A prospective hospital-based study of the clinical impact of non-severe acute respiratory syndrome (non-SARS)-related human coronavirus infection. Clin Infect Dis. 2006;43:1009. doi: 10.1086/507898.
    1. Garbino J, Gerbase MW, Wunderli W, Deffernez C, Thomas Y, Rochat T, et al. Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact. Am J Respir Crit Care Med. 2004;170:1197. doi: 10.1164/rccm.200406-781OC.
    1. Koenighofer M, Lion T, Bodenteich A, Prieschl-Grassauer E, Grassauer A, Unger H, Mueller CA, Fazekas T. Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials. Multidisciplinary Respir Med 2014, 9:57
    1. Arruda E, Pitkaranta A, Witek TJ, Doyle CA, Hayden FG. Frequency and natural history of rhinovirus infections in adults during autumn. J Clin Microbiol. 1997;35:2864–2868.
    1. Rabago D, Pasic T, Zgierska A, Mundt M, Barrett B, Maberry R. The efficacy of hypertonic saline nasal irrigation for chronic sinonasal symptoms. Otolaryngol Head Neck Surg. 2005;133:3–8. doi: 10.1016/j.otohns.2005.03.002.
    1. Rabago D, Zgierska A, Mundt M, Barrett B, Bobula J, Maberry R. Efficacy of daily hypertonic saline nasal irrigation among patients with sinusitis: a randomized controlled trial. J Fam Pract. 2002;51:1049–1055.
    1. Kassel JC, King D, Spurling GK. Saline nasal irrigation for acute upper respiratory tract infections. Cochrane Database Syst Rev. 2010;3:CD006821.
    1. Carlucci MJ, Ciancia M, Matulewicz MC, Cerezo AS, Damonte EB. Antiherpetic activity and mode of action of natural carrageenans of diverse structural types. Antiviral Res. 1999;43:93–102. doi: 10.1016/S0166-3542(99)00038-8.
    1. Talarico LB, Damonte EB. Interference in dengue virus adsorption and uncoating by carrageenans. Virology. 2007;363:473–85. doi: 10.1016/j.virol.2007.01.043.
    1. Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, et al. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006;2:e69–ff. doi: 10.1371/journal.ppat.0020069.
    1. Barrett B, Brown R, Rakel D, Mundt M, Bone K, Barlow S, et al. Echinacea for treating the common cold: a randomized controlled trial. Ann Intern Med. 2010;153(12):769–777. doi: 10.7326/0003-4819-153-12-201012210-00003.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe